CMBA
GHDX

C.M. Bidwell & Associates’s Genomic Health, Inc. GHDX Stock Holding History

C.M. Bidwell & Associates’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,185
Closed -$83K – 474
2019
Q1 		$83K Buy
+1,185
New +$87.9K 0.08% 195

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

C.M. Bidwell & Associates's GHDX Position: Q2 2019 in Review

C.M. Bidwell & Associates sold out of Genomic Health, Inc. (GHDX) in Q2 2019, closing a stake of 1,185 shares — an estimated $83K sold.

C.M. Bidwell & Associates first reported a position in GHDX in Q1 2019 and held it in 1 quarter. The position peaked at $83K in Q1 2019. 215 funds tracked by Wall St. Rank hold GHDX as of Q2 2019.

  • C.M. Bidwell & Associates reported no remaining Genomic Health, Inc. position as of Q2 2019 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 1,185 Genomic Health, Inc. shares in Q2 2019, an estimated $83K.
  • C.M. Bidwell & Associates first reported a position in Genomic Health, Inc. in Q1 2019 and held it in 1 quarter.
  • C.M. Bidwell & Associates's Genomic Health, Inc. position peaked at $83K in Q1 2019.
  • 215 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q2 2019.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2019, filed 7 Aug 2019.